Rare CNS Growth Harmony focuses on rare neurological diseases across sleep/wake, neurobehavioral, and rare epilepsy. Q1 2026 revenue of $215M and guidance over $1B show a strong commercial platform; opportunities exist to partner for expansion into adjacent CNS indications, co-promotion with neurology specialists, and payer-ready access strategies.

Pipeline Licensing EPX-100 (clemizole hydrochloride) is in Phase 3 for Dravet syndrome with data to be presented at AAN 2026. This asset offers potential for strategic partnerships to co-develop or license global rights, leveraging its orexin-2 receptor mechanism to address rare epilepsies.

IP Advantage Harmony recently filed patent infringement suits related to an amorphous form of pitolisant hydrochloride, indicating a robust IP moat around WAKIX. This can support licensing discussions and deter competitors, creating a more favorable environment for partnerships and supply deals.

Financial Readiness A CFO transition to Glenn Reicin alongside a revenue trajectory exceeding $1B signals improved financial discipline and growth readiness, making Harmony attractive for co-development deals, manufacturing partnerships, and milestone-driven collaborations with favorable terms.

Digital Commercial The company uses Veeva Systems and other modern tech tools, indicating mature commercial operations and data capabilities. This enables targeted outreach to neurology clinics, sleep centers, and epilepsy centers, plus potential payer analytics, patient access programs, and streamlined collaborations.